Regulatory Compliance

Singapore – September 21, 2026 -- Specialised Therapeutics (ST) has expanded its partnership with Incyte Biosciences International to commercialise, distribute, and register ruxolitinib cream, marketed as Opzelura, in Australia.

ST gains rights to market Opzelura for vitiligo and atopic dermatitis in Australia

Under the expanded agreement, Incyte will continue to develop and manufacture ruxolitinib cream, a topical Janus kinase (JAK) inhibitor, while ST takes on regulatory submissions, medical affairs, marketing, and distribution across the Australian market. The drug is approved in the U.S. and European Union for treating non-segmental vitiligo and mild-to-moderate atopic dermatitis in patients who do not respond adequately to standard topical therapies.

Urbandale, Iowa – September 21, 2026 -- Small businesses in the Des Moines metro should secure general liability insurance first, followed by property coverage and workers' compensation, according to insights from Ben Buenzow, an insurance expert at Buenzow Insurance Group, featured in a HelloNation article.

General liability insurance forms the first line of financial defense for small operators

The coverage protects companies against claims of bodily injury or property damage stemming from business operations, addressing risks from customers, vendors, or visitors. Legal costs and settlements tied to such claims can be significant enough to threaten a small firm's cash flow without this protection in place.

Atlanta – September 21, 2026 -- Siemba has launched automated testing for insecure direct object reference (IDOR) flaws, cutting the time to scan a 200-endpoint API collection to under an hour, a task the company says has typically taken human testers days or weeks.

IDOR ranks first among OWASP's API Security Top 10 risks

IDOR, classified by OWASP as broken object level authorization, occurs when an endpoint fails to verify that a caller-supplied identifier belongs to them, allowing a single changed number in a request to expose another user's data. Siemba's Chief Security Officer Sandhya Prashanth said the flaw "drives a huge share of real-world breaches" and requires little more than systematic testing across every endpoint to detect.

New York and Suzhou, China – September 21, 2026 -- Accro Bioscience Inc. has dosed its first patient in a Phase IIb trial testing AC-101, a selective RIPK2 inhibitor, in patients with moderate-to-severe ulcerative colitis (UC).

Trial spans roughly 50 clinical sites with three treatment arms

The multicenter, double-blind, placebo-controlled study is designed across approximately 50 clinical sites and includes two AC-101 dose cohorts plus a placebo control arm. The primary endpoint is clinical remission rate at Week 12, with exploratory endpoints covering histologic remission and long-term maintenance of clinical and histologic remission.

Beijing – September 21, 2026 -- Nearly 400 domestic and international delegates gathered at the Beijing Municipal Administrative Center (BMC) on September 17 as the Beijing Green Development Forum 2026 opened, unveiling a new blue book on the capital's green economy and a standards-led transition initiative backed by more than 20 institutions.

Hosted by Asia Data Group and organized by ADG Expo Group, the forum carried the theme "Green Empowerment, Low-Carbon Symbiosis" and drew support from Global Honorary Partner Huaxia Bank and strategic partner Beijing Energy Holding Co., Ltd. International bodies including the World Green Design Organization, C40 Cities Climate Leadership Group, and the Center for China & Globalization backed the event.

Beijing – September 21, 2026 -- Nearly 390 representatives from 41 countries and regions gathered in Beijing on September 18 for the China Arbitration Summit 2026, an event that drew over 5.14 million online views from 55 countries and regions.

Four institutions co-host flagship dispute-resolution forum

The China High-level Dialogue on Maritime and Commercial Arbitration was jointly organized by the China International Economic and Trade Arbitration Commission (CIETAC), the China Maritime Arbitration Commission (CMAC), the United Nations Commission on International Trade Law (UNCITRAL), and the All China Lawyers Association (ACLA). The summit served as the flagship event of the 14th China Arbitration Week, which ran 77 seminars across 40 cities in 10 countries and regions from September 15 to 21.

Ras Al Khaimah – September 21, 2026 -- ARIDGE, formerly XPENG AEROHT and Asia's largest flying car company, has signed a strategic cooperation agreement with the Emirate of Ras Al Khaimah to establish what both parties describe as the world's first regulatory sandbox dedicated to personal low-altitude flight.

The agreement was signed in the presence of His Highness Sheikh Saud bin Saqr Al Qasimi, UAE Supreme Council Member and Ruler of Ras Al Khaimah, under oversight of the UAE General Civil Aviation Authority (GCAA). The deal makes ARIDGE the first Chinese flying car company to enter a national-level regulatory sandbox in the Middle East.

Rochester, Mich. – September 21, 2026 -- Par Health is voluntarily recalling two lots of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection 400 mcg/100 mL (4 mcg/mL) at the hospital level after detecting particulate matter identified as cellulose or stopper material.

Contaminated vials carry risk of pulmonary emboli and vessel occlusion

The FDA-notified recall covers Lots 87558 and 88802, which were distributed nationwide to wholesalers between September 21, 2026 and September 21, 2026. Par Health warned that administering the affected product carries a reasonable probability of causing life-threatening adverse health consequences, including pulmonary emboli, occlusions of other blood vessels that can lead to tissue death and organ damage, and inflammation of vein walls that may result in clotting. The company said it has not received any adverse event reports tied to the recall to date.

Fountain Valley, Calif. – September 21, 2026 -- MemorialCare's Long Beach Medical Center and Saddleback Medical Center have received the American Heart Association's Get With The Guidelines® - Stroke Gold Plus quality achievement award, recognizing stroke treatment aligned with nationally validated clinical guidelines. Long Beach Medical Center additionally earned the Get With The Guidelines® - Heart Failure Gold Plus award for reducing readmissions and increasing healthy days at home for heart failure patients.

Long Beach Medical Center collects four additional Target Honor Roll designations

Long Beach Medical Center received the Target: Stroke Honor Roll Elite Plus, Advanced Therapy, Target: Type 2 Diabetes Honor Roll, and Target: Heart Failure Honor Roll Optimal. Saddleback Medical Center secured the Target: Stroke Honor Roll Elite Plus and Target: Type 2 Diabetes Honor Roll designations.

Sheridan, Wyoming – September 21, 2026 -- The global remote patient monitoring (RPM) market is set to grow from $34.5 billion in 2026 to $62.2 billion by 2031, a 12.5% compound annual growth rate, according to a new study by Wissen Research.

Reimbursement codes and readmission penalties push hospitals toward RPM at scale

Dedicated CMS billing codes are giving U.S. providers a recurring revenue incentive to deploy RPM, while health systems use the technology to avoid costly 30-day readmission penalties tied to chronic disease relapse. Cardiovascular disease held the largest application share in 2025, reflecting the clinical and financial burden of heart failure, atrial fibrillation and hypertension.